Yarrow Bioscience (NASDAQ:YARW) Earns Buy Rating from Analysts at BTIG Research

Analysts at BTIG Research initiated coverage on shares of Yarrow Bioscience (NASDAQ:YARW) in a report released on Monday,Benzinga reports. The brokerage set a “buy” rating and a $58.00 price target on the stock. BTIG Research’s target price points to a potential upside of 65.62% from the company’s current price.

Separately, TD Cowen initiated coverage on Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a “buy” rating on the stock. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $58.00.

Yarrow Bioscience Price Performance

Yarrow Bioscience stock opened at $35.02 on Monday. Yarrow Bioscience has a 52-week low of $14.02 and a 52-week high of $46.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.